Brean Capital Downgrades Keryx Biopharmaceuticals (KERX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Stifel Downgrades Keryx Biopharmaceuticals (KERX) to Hold
August 2, 2016 6:59 AM EDTStifel downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Hold.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.72 yesterday.
... MoreFBR Capital Downgrades Keryx Biopharmaceuticals (KERX) to Market Perform
August 2, 2016 6:23 AM EDTFBR Capital downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Outperform to Market Perform with a price target of $7.00 (from $13.00) following news of a production-related interruption in Auryxia supply.
Analyst Christopher James commented, "Yesterday, August 1, Keryx hosted a conference call to review its 2Q16 financial performance and... More
Maxim Group Downgrades Keryx Biopharmaceuticals (KERX) to Hold
August 1, 2016 10:00 AM EDTMaxim Group downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Hold on manufacturing disruption.
Analyst Jason Kolbert commented:
We are lowering our rating to Hold from Buy based on news that Keryx will now face manufacturing disruption(s) for at least one quarter and possibly more. We have also adjusted our assumptions for COGS (higher) in the 25% range migrating slightly lower over time. In... MoreKeryx Biopharma (KERX) Announces Auryxia Supply Interruption; Provides Q2 Results
August 1, 2016 7:32 AM EDTKeryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that an interruption in the supply of Auryxia® (ferric citrate) tablets is imminent due to a production-related issue converting active pharmaceutical ingredient (API) to finished drug product. Keryx expects to make Auryxia available to patients when supply of Auryxia is back to adequate levels, which Keryx anticipates will be during the fourth quarter of 2016.
We take our responsibility to patients and the treating community very seriously and recognize the impact this interruption of supply will cause for patients and their healthcare providers, said Greg Madison, chief executive officer of Keryx... More
